Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| X23-0202 & 2023/ETH00540 | Other Identifier | RPAH Ethics and Governance Office |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this clinical trial is to investigate the effectiveness of two rehabilitation programs for individuals who have undergone amputations and are experiencing phantom limb pain. The main question it aims to answer is:
- In individuals who have undergone amputations and are experiencing phantom limb pain, what is the effectiveness of a progressive rehabilitation program compared to a treatment program consisting of transcutaneous electrical nerve stimulation and cranial electrical stimulation on reducing pain intensity and pain interference?
A total of 208 participants will be randomized into two groups: progressive rehabilitation program and stimulation devices. The progressive rehabilitation program includes pain science education, sensory training, and left/right judgements, imagined movements and mirror therapy. The treatment program for the group receiving the stimulation devices includes transcutaneous electrical nerve stimulation and cranial electrical stimulation. Both interventions will be delivered via eight, up to 1-hour telehealth sessions. Outcome measures will be assessed at baseline and weeks 12, 24 and 52.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Progressive rehabilitation program | Experimental | The progressive rehabilitation program is a multicomponent intervention, including pain science education, sensory training, implicit and explicit motor imagery, and mirror therapy. |
|
| Stimulation devices | Experimental | The treatment program includes Transcutaneous Electrical Nerve Stimulation and Cranial Electrical Stimulation. Participants will complete activities at a self-directed pace following a standard progression protocol. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Progressive rehabilitation program | Other | Twelve-week treatment program delivered via eight, up to 1-hour telehealth sessions. The first five sessions will be scheduled every week, and the final three sessions will be scheduled fortnightly. Participants will also be prescribed approximately 15-30 minutes of home activities daily. The treatment program includes pain science education, sensory training, implicit and explicit motor imagery, and mirror therapy. Participants will complete activities at a self-directed pace following a standard progression protocol. Participant adherence will be measured via session attendance and self-report therapy diaries. |
| Measure | Description | Time Frame |
|---|---|---|
| Pain intensity | Average pain intensity over the previous 7 days assessed using the 11-point Numerical Pain Rating Scale. | Week 12 post-randomisation |
| Pain interference | Average pain interference with function over the previous 7 days assessed using the 0-10 Pain Interference Scale of the Brief Pain Inventory. | Week 12 post-randomisation |
| Measure | Description | Time Frame |
|---|---|---|
| Pain intensity | Average pain intensity over the previous 7 days assessed using the 11-point Numerical Pain Rating Scale. | Weeks 24 and 52 post-randomisation |
| Pain interference | Average pain interference with function over the previous 7 days assessed using the 0-10 Pain Interference Scale of the Brief Pain Inventory. |
| Measure | Description | Time Frame |
|---|---|---|
| Pain Self-Efficacy Questionnaire (mediator) | Pain self efficacy measured using the Pain Self-Efficacy Questionnaire. The total score of this questionnaire ranges from 0 to 60, with higher scores indicating higher self-efficacy and functioning despite ongoing pain. | Weeks 6 and 10 post-randomisation |
| Concept of Pain Inventory (mediator) |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| James H McAuley, PhD | Contact | +61293991266 | j.mcauley@neura.edu.au | |
| Rafael Z Pinto, PhD | Contact | r.zambelli@neura.edu.au |
| Name | Affiliation | Role |
|---|---|---|
| James H McAuley, PhD | Neuroscience Research Australia | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Neuroscience Research Australia | Recruiting | Randwick | New South Wales | 2031 | Australia |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 37214633 | Background | Limakatso K, Cashin AG, Williams S, Devonshire J, Parker R, McAuley JH. The Efficacy of Graded Motor Imagery and Its Components on Phantom Limb Pain and Disability: A Systematic Review and Meta-Analysis. Can J Pain. 2023 May 17;7(1):2188899. doi: 10.1080/24740527.2023.2188899. eCollection 2023. |
| Label | URL |
|---|---|
| Trial website | View source |
Not provided
De-identified individual participant data will be made to interested researchers only upon reasonable request and once the proposed research project has received separate ethics approval from a Human Research Ethics Committee.
Request to the data custodian, the Principal Investigator (j.mcauley@neura.edu.au).
Data will be made available after the publication of study reports. There is no end date for the availability of study data.
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D010591 | Phantom Limb |
| ID | Term |
|---|---|
| D010468 | Perceptual Disorders |
| D019954 | Neurobehavioral Manifestations |
| D009461 | Neurologic Manifestations |
| D009422 | Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Stimulation devices | Other | Twelve-week treatment program delivered via eight, up to 1-hour telehealth sessions. The first five sessions will be scheduled every week, and the final three sessions will be scheduled fortnightly. Participants will also be prescribed approximately 15-30 minutes of home activities daily. The treatment program includes transcutaneous electrical nerve stimulation and cranial electrical stimulation. Participants will complete activities at a self-directed pace following a standard progression protocol. Participant adherence will be measured via session attendance and self-report therapy diaries. |
|
| Weeks 24 and 52 post-randomisation |
| Pain severity | Average pain intensity over the previous 7 days assessed using the 0-10 Pain Severity Scale of the Brief Pain Inventory. | Weeks 12, 24 and 52 post-randomisation |
| Sleep subscale of the Brief Pain Inventory's Pain Interference Scale | Sleep Quality assessed using the Sleep subscale of the Brief Pain Inventory's Pain Interference Scale. The participants will rate the interference of pain with sleep on a 0-10 scale where "0" represents "does not interfere" and "10" represents "completely interferes". | Weeks 12, 24 and 52 post-randomisation |
| PROMIS Self-Efficacy Manage Symptoms | Pain Self-efficacy assessed using PROMIS Self-Efficacy Manage Symptoms (Computer Adaptive Test) (28-item version; higher scores mean more self-efficacy). | Weeks 12, 24 and 52 post-randomisation |
| PROMIS Depression | Emotional distress and depression assessed using PROMIS Depression (Computer Adaptive Test) (28-item version; higher scores mean more depression). | Weeks 12, 24 and 52 post-randomisation |
| EuroQol 5-Dimension 5-Level (EQ-5D-5L) | Health-Related Quality of Life assessed using the EQ-5D-5L dimensions scale range, 1-5; higher scores indicate better quality of life) and health thermometer (range, 0-100; higher scores indicate better quality of life). | Weeks 12, 24 and 52 post-randomisation |
| Global Perceived Effect Scale | Perception of recovery assessed using the Global Perceived Effect scale (range from -5 to +5; higher scores mean greater improvement). | Weeks 12, 24 and 52 post-randomisation |
| Adverse events | Adverse events assessed via self-report. | From randomisation to week 12 post-randomisation |
| Adherence to treatment | Adherence to treatment assessed via session attendance and self-report (diary), including frequency per week and duration per day. | From randomisation to week 12 post-randomisation |
| Total health-care costs | Total health-care costs will be estimated as the trial intervention costs and outside trial health-care resource use attributable to phantom limb pain from the Medicare Benefits Scheme and Pharmaceutical Benefits Scheme. Quality-adjusted life-years (QALYs) from the EQ-5D-5L using the Australian utility weights will also be used in the trial-based cost-utility analysis. | Weeks 12, 24 and 52 post-randomisation |
| Treatment rationale credibility | Treatment rationale credibility assessed using the Credibility and Expectancy Questionnaire. The total score ranges from 0 to 48, with lower scores indicating lower credibility. | Week 1 post-randomisation |
Beliefs and knowledge of pain science assessed using the Concept of Pain Inventory. This is a 13-item questionnaire with scores ranging from 0 to 52 points, with higher scores reflecting greater alignment with contemporary pain science. |
| Weeks 6 and 10 post-randomisation |
| Pain Catastrophising Scale (mediator) | Pain catastrophising assessed using the Pain Catastrophising Scale. The total score ranges from 0 to 52, with higher scores indicating a higher level of catastrophising. | Weeks 6 and 10 post-randomisation |
| Phantom limb movement scale (mediator) | The ability to move the phantom limb assessed on an 11-point Numerical Rating Scale (0: No movement at all, 10: Complete range of movement as if the limb were still present). | Weeks 6 and 10 post-randomisation |
| Phantom limb body perception disturbance scale (mediator) | The phantom limb body perception disturbances assessed using 4 questions measuring ownership, awareness, attention and emotional feelings on an 11-point Numerical Rating Scale (range, 0-40; lower scores indicate more severe body perception disturbances). Adapted from the Bath Complex Regional Pain Syndrome body perception disturbance scale. | Weeks 6 and 10 post-randomisation |
| D010149 | Pain, Postoperative |
| D011183 | Postoperative Complications |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D012816 | Signs and Symptoms |
| D010146 | Pain |